

## Maxigen Biotech Inc. 2017 Annual Shareholders Meeting

One. The Company will host the 2017 Annual Shareholders Meeting on Monday, June 26, 2017 at 10:30 A.M. (shareholder sign-in registration will commence at 10 o'clock at the venue of the meeting) at the Company's Meeting Room (3F., No. 88, Sec. 1 Ke-Ji Rd., Guishan District, Taoyuan City). Please see below for contents of the meeting:

(1) Management Presentation: 1. the Company's 2016 Business Report 2. Supervisor's Review Report on 2016 Financial Statements

(2) Matters to be Reported: 1. Adoption of the Company's 2016 Business Report and Financial Statements. 2. Adoption of the Company's 2016 Proposal of Appropriation of Profit & Loss.

(3) Matters to be Discussed 1: 1. Amendment of the Company's Articles of Association. 2. Amendment of the Company's 'Procedures for Acquisition or Disposal of Assets'

(4) Elections: Elections of the Company's 8th Board of Directors and Supervisors.

(5) Matters to be Discussed 2: Release the Company's Newly Appointed Directors from Prohibitions from Participation in Competitive Business.

(6) Questions and Motions

Two. Nine seats of Directors (including two Independent Directors) and three seats of Supervisors will be elected from this Shareholders Meeting. A nomination system will be adopted. The list of Independent Directors includes: Si-Tang Teng and Shi-Hsiung Teng. Should any investor wish to inquire about the education and work experiences of the nominees, please visit the MOPS's 'Announcement Inquiry' at <http://mops.twse.com.tw>.

Three. The release of the competitive business engagements discussed by the Company is pursuant to provisions provided by Article 209 of the Company Act. The shareholders will be requested to provide consent to release the competitive business engagement prohibition of the newly elected Directors and/or their representatives.

Four. All transfer of Company shares are halted between April 28, 2017 to June 26, 2017 pursuant to Article 165 of the Company Act.

Five. In addition to the meeting announcement, we have also hereby attached a set of sign-in card and power of attorney to this announcement. Please try to attend to your best ability. If you wish to attend in person, please either sign or seal in the third section - the attendance RSVP form, and attendance will be taken at the venue on the date of the meeting. There is no need to mail the form back. If you wish to attend by proxy, please fill in the third section - power of attorney and either sign or seal. Please fold accordingly and to mail (or deliver) to the Shareholding Agency Department at First Securities Inc., the Company's designated agency for shareholding matters, five days before the meeting. The shareholding agency will make an attendance card for the proxy and remit the card to him/her to proceed with sign-in process at the Shareholders Meeting. (Please bring your personal identification card for verification when attending as a proxy.)

Six. In case any shareholder wishes to receive additional power of attorney document. The Company will compile a list of Requested Personnel and Information and disclose the form in the Securities & Futures Institute (SFI). Should any shareholder wish to inquire this information, please enter the following website: <http://free.sfi.org.tw> for the 'Free Inquiry System for Announcement on Information Regarding Power of Attorney' and click on 'Enter here for inquiry on public meeting information on powre of attorney' and enter keywords that you wish to inquire for. (Stock code: 1783)

Seven. The Company has delegated the verification of power of attorney for this Shareholders Meeting to Shareholding Agency Department at First Securities Inc.

To  
Esteemed Shareholders



**Best regards, Board of Directors of Maxigen Biotech Inc.**